Esketamine nasal spray
Indication
Treatment of resistant depression (NICE TA854)
NICE TA854 - Esketamine nasal spray for treatment-resistant depression
Black
Brand:
Spravato
Nice TA:
854
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
1.1 Esketamine nasal spray with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is not recommended, within its marketing authorisation, for treatment-resistant depression that has not responded to at least 2 different antidepressants in the current moderate to severe depressive episode in adults.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: